Pharmstandard Value Sinks $1.4 Billion on Deal Skepticism

OAO Pharmstandard tumbled for a third day as Russia’s biggest pharmaceutical company presses on with the $630 million purchase of a company affiliated to one of its board members.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.